NYSE:GMED Globus Medical (GMED) Stock Price, News & Analysis $85.10 +0.29 (+0.34%) As of 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Globus Medical Stock (NYSE:GMED) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Globus Medical alerts:Sign Up Key Stats Today's Range$84.03▼$85.7350-Day Range$75.65▼$96.6852-Week Range$51.79▼$101.40Volume1.83 million shsAverage Volume1.36 million shsMarket Capitalization$11.55 billionP/E Ratio19.79Dividend YieldN/APrice Target$106.36Consensus RatingModerate Buy Company Overview Globus Medical, Inc. (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes. In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room. The ExcelsiusGPS® robotic guidance system, for example, integrates real-time imaging with robotic arm technology to enable surgeons to perform complex procedures with greater accuracy. The company also offers an array of trauma and orthopaedic solutions, such as bone graft substitutes and joint reconstruction implants, to address a broad spectrum of musculoskeletal conditions. Globus Medical serves surgeons and patients across North America, Europe, Asia, Latin America and the Middle East through a combination of direct sales and distribution partnerships. Under the leadership of founder and Executive Chairman David C. Paul and President and Chief Executive Officer Glenn J. Shapiro, the company has built a global commercial infrastructure and invested in research and development to drive innovation. Its commitment to surgical education and customer support further reinforces its position in the competitive medical device landscape.AI Generated. May Contain Errors. Read More Globus Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScoreGMED MarketRank™: Globus Medical scored higher than 95% of companies evaluated by MarketBeat, and ranked 30th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingGlobus Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 2 strong buy ratings, 9 buy ratings, 5 hold ratings, and no sell ratings.Upside PotentialGlobus Medical has a consensus price target of $106.36, representing about 24.1% upside from its current price of $85.68.Amount of Analyst CoverageGlobus Medical has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Globus Medical's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth6.75% Earnings GrowthEarnings for Globus Medical are expected to grow by 6.75% in the coming year, from $4.74 to $5.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Globus Medical is 19.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Globus Medical is 19.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.95.Price to Earnings Growth RatioGlobus Medical has a PEG Ratio of 1.75. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGlobus Medical has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Globus Medical's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.83% of the float of Globus Medical has been sold short.Short Interest Ratio / Days to CoverGlobus Medical has a short interest ratio ("days to cover") of 3.52, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Globus Medical has recently decreased by 5.84%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGlobus Medical does not currently pay a dividend.Dividend GrowthGlobus Medical does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment0.64 News SentimentGlobus Medical has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Globus Medical this week, compared to 6 articles on an average week.Search Interest23 people have searched for GMED on MarketBeat in the last 30 days. This is an increase of 229% compared to the previous 30 days.MarketBeat Follows9 people have added Globus Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Globus Medical insiders have not sold or bought any company stock.Percentage Held by Insiders18.38% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.16% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Globus Medical's insider trading history. Receive GMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GMED Stock News HeadlinesGlobus Medical Uses Generative AI And M&A To Reshape Growth ProfileMay 22, 2026 | finance.yahoo.comBull of the Day: Globus Medical (GMED)May 21, 2026 | theglobeandmail.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 26 at 1:00 AM | Porter & Company (Ad)Jim Cramer on Globus Medical: “There Is Not a Lot of Money to Be Made in This One”May 20, 2026 | insidermonkey.comGlobus Medical EPS Surges as Margins ExpandMay 19, 2026 | tipranks.comNeedham Raises its Price Target on Globus Medical (GMED)May 19, 2026 | insidermonkey.comGlobus Medical Inc Class AMay 17, 2026 | cnn.com5 must-read analyst questions from Globus Medical’s Q1 earnings callMay 14, 2026 | msn.comSee More Headlines GMED Stock Analysis - Frequently Asked Questions How have GMED shares performed this year? Globus Medical's stock was trading at $87.39 on January 1st, 2026. Since then, GMED shares have decreased by 2.0% and is now trading at $85.68. How were Globus Medical's earnings last quarter? Globus Medical, Inc. (NYSE:GMED) released its earnings results on Thursday, May, 7th. The medical device company reported $1.12 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.20. Globus Medical's quarterly revenue was up 27.0% compared to the same quarter last year. Read the conference call transcript. Is Globus Medical buying back stock? Globus Medical's board approved a share repurchase plan on Thursday, May 15th 2025, which permits the company to repurchase $500,000,000 in shares, according to EventVestor. This means that the company could buy up to 6.3% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's board of directors believes its stock is undervalued. When did Globus Medical IPO? Globus Medical (GMED) raised $200 million in an IPO on Friday, August 3rd 2012. The company issued 11,764,705 shares at $16.00-$18.00 per share. Who are Globus Medical's major shareholders? Top institutional shareholders of Globus Medical include Janus Henderson Group PLC (5.62%), Sculptor Capital LP (2.25%), Dimensional Fund Advisors LP (1.31%) and Boston Trust Walden Corp (0.93%). Insiders that own company stock include David D Davidar, Ann D Rhoads, Leslie V Norwalk, Stephen T Zarrilli, Daniel T Scavilla, Dan Lemaitre, Kyle Kline, Kelly Huller and Keith W Pfeil. View institutional ownership trends. How do I buy shares of Globus Medical? Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Globus Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Globus Medical investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Arista Networks (ANET), Advanced Micro Devices (AMD) and ServiceNow (NOW). Company Calendar Last Earnings5/07/2026Today5/26/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 6 days, GMED's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED INSTRUMENTS Sub-IndustryHealth Care Equipment Current SymbolNYSE:GMED CIK1237831 Webwww.globusmedical.com Phone(610) 930-1800Fax610-930-2042Employees6,000Year Founded2003Price Target and Rating Average Price Target for Globus Medical$106.36 High Price Target$123.00 Low Price Target$64.00 Potential Upside/Downside+25.0%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)$4.30 Trailing P/E Ratio19.79 Forward P/E Ratio17.95 P/E Growth1.75Net Income$537.87 million Net Margins18.92% Pretax Margin21.24% Return on Equity13.46% Return on Assets11.65% Debt Debt-to-Equity RatioN/A Current Ratio4.56 Quick Ratio2.95 Sales & Book Value Annual Sales$2.94 billion Price / Sales3.93 Cash Flow$6.30 per share Price / Cash Flow13.50 Book Value$34.86 per share Price / Book2.44Miscellaneous Outstanding Shares135,740,000Free Float110,795,000Market Cap$11.55 billion OptionableOptionable Beta1.00 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NYSE:GMED) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYou cannot escape this realityThe last time something like this happened was 1974 - a secret deal that quietly determined the financial fate...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredNearly Half of Americans Are ExposedDr. David Eifrig, former Goldman Sachs insider and CEO of one of the largest financial research firms in the w...Stansberry Research | SponsoredI was right about SpaceX. Now here's the part that mattersGoldman Sachs and JP Morgan have already been tied to allocations surrounding the SpaceX deal. When the bigges...The Oxford Club | SponsoredYour computer is about to become a museum pieceFor 67 years, chip-making meant slicing a single silicon wafer into hundreds of pieces. Three companies just a...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Globus Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Globus Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
